Abiopharma

🔍 Fadda Luca (Executive)

Company: TIM S.A. (TIMB)

Report Date: 2026-05-05

Detailed Transactions and Holdings:

• Acquired 32,290 shares of Common Shares (Direct)
  Date: 2026-05-05 | Code: A | equity_swap_involved: false | shares_owned_after: 32,290.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 7,655 shares of Common Shares (Direct)
  Date: 2026-05-05 | Code: A | equity_swap_involved: false | shares_owned_after: 39,945.00 | transaction_form_type: 4 | Footnotes: F2
• Acquired 1,993 shares of Restricted Shares (Derivative)
  Date: 2026-05-05 | Code: A | equity_swap_involved: false | shares_owned_after: 13,284.00 | transaction_form_type: 4 | Footnotes: F3, F4, F5, F5

Footnotes:

• F1: Represents the number of common shares earned (including any accrued dividend equivalent units), as a result of the Issuer's Board of Director's (the "Board") certification to the achievement of performance for the performance shares granted in 2023. These shares vest 20%, 30% and 50% on the first three anniversaries of the grant date, respectively, subject to the Reporting Person's continued service through each such vesting date.
• F2: Represents the number of common shares earned (including any accrued dividend equivalent units), as a result of the Board's certification to the achievement of performance for portions of the performance shares granted in 2024. These shares vest 10%, 20% and 70% on the first three anniversaries of the grant date, respectively, subject to the Reporting Person's continued service through each such vesting date.
• F3: Each restricted share represents a contingent right to receive one common share minus withholding taxes.
• F4: Represents dividend equivalent units with respect to restricted shares accrued upon approval by the Board on May 5, 2026.
• F5: These restricted shares vest on July 31, 2026.